Association of adverse effects with high serum posaconazole concentrations.
drug monitoring
posaconazole
posaconazole toxicity
supratherapeutic posaconazole
triazoles
Journal
Medical mycology
ISSN: 1460-2709
Titre abrégé: Med Mycol
Pays: England
ID NLM: 9815835
Informations de publication
Date de publication:
02 Aug 2023
02 Aug 2023
Historique:
received:
31
05
2023
revised:
13
07
2023
accepted:
01
08
2023
pmc-release:
03
08
2024
medline:
14
8
2023
pubmed:
4
8
2023
entrez:
3
8
2023
Statut:
ppublish
Résumé
Posaconazole therapeutic drug monitoring (TDM) is widely utilized to assess therapeutic efficacy and safety; however, clinical effects of very high serum concentrations are unknown. A retrospective review of 90 patients receiving posaconazole for treatment or prophylaxis of invasive fungal infections with serum concentrations ≥3000 ng/mL from 1/1/2019 to 4/30/2021 evaluated the incidence and type of adverse drug reactions (ADRs). Symptomatic ADRs were very common in patients with posaconazole concentrations of ≥5000 ng/mL and 3000-4999 ng/mL (80% vs. 58.8%; P = 0.31). Posaconazole TDM should be performed for both treatment and prophylaxis indications and dose decrease for serum concentrations >3000 ng/mL should be considered. Drug level monitoring is commonly used to evaluate appropriate dosing and effectiveness of posaconazole, a medication used to treat fungal infections. Patients with high levels commonly had side effects. Posaconazole monitoring should be completed, and doses reduced when levels are high.
Autres résumés
Type: plain-language-summary
(eng)
Drug level monitoring is commonly used to evaluate appropriate dosing and effectiveness of posaconazole, a medication used to treat fungal infections. Patients with high levels commonly had side effects. Posaconazole monitoring should be completed, and doses reduced when levels are high.
Identifiants
pubmed: 37537152
pii: 7236866
doi: 10.1093/mmy/myad079
pmc: PMC10414342
pii:
doi:
Substances chimiques
Antifungal Agents
0
posaconazole
6TK1G07BHZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002377
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.
Références
J Clin Epidemiol. 1993 Nov;46(11):1323-30
pubmed: 8229110
Clin Infect Dis. 2020 Jun 10;70(12):2593-2598
pubmed: 31403165
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28167540
J Clin Epidemiol. 1993 Nov;46(11):1331-6
pubmed: 8229111
Antimicrob Agents Chemother. 2015 Aug;59(8):4914-8
pubmed: 26055378
Lancet. 2021 Feb 6;397(10273):499-509
pubmed: 33549194
Curr Fungal Infect Rep. 2016;10:51-61
pubmed: 27358662